Improving Quality and Potency Testing for Umbilical Cord Blood: A New Perspective.

Area of Science:

• Hematology
• Transplantation Medicine
• Stem Cell Biology

Background:

• Current umbilical cord blood (UCB) testing for hematopoietic stem cell transplantation relies on parameters like total nucleated cell count and viability.
• These standard tests do not adequately assess the quality and potency of stem cells, potentially leading to graft failure.
• Existing statutes mandate high-quality and potent UCB stem cells for successful transplantation.

Purpose of the Study:

• To critically review current UCB testing methods for hematopoietic stem cell transplantation.
• To highlight the inadequacy of existing tests in determining stem cell quality and potency.
• To propose improved UCB processing and testing strategies for enhanced transplant efficacy.

Main Methods:

• Review of current UCB testing methodologies, including total nucleated cell (TNC) count, viability, CD34-positive cell content, and colony-forming unit assays.
• Analysis of new evidence questioning the reliability of data derived from the TNC fraction.
• Proposal for processing UCB to the mononuclear cell fraction and implementing new quality and potency testing technologies.

Main Results:

• Current UCB testing practices, particularly those relying on the TNC fraction, underestimate stem cell functionality and quality.
• This underestimation contributes to high graft failure rates and non-compliance with regulatory requirements for stem cell quality.
• No cord blood units have been tested for stem cell quality or potency to date.

Conclusions:

• Existing UCB testing protocols are insufficient to guarantee stem cell quality and potency for transplantation.
• New scientific evidence challenges current processing and testing practices mandated by regulatory bodies.
• Implementing mononuclear cell fraction processing and advanced quality/potency assays can significantly reduce graft failure rates and improve patient safety.